Targeted therapies, diagnostics remain concern for severe asthma

There is an urgent need for improved diagnostic tools and targeted therapies to address the gap in care for patients with severe asthma, specifically for those with T-helper cell type 2 (T2)-low asthma, a subtype lacking typical inflammatory biomarkers, according to a recent report.

T2-low asthma presents unique challenges due to the absence of eosinophils and immunoglobulin E (IgE), which complicates both diagnosis and treatment. And treatments currently available are primarily focused on eosinophilic and allergic inflammation. This leaves patients with non-eosinophilic or neutrophilic asthma without adequate options.

The report by GlobalData, a data and analytics company, showed that while T2-high asthma has benefitted from targeted biologic treatments, T2-low asthma remains largely underserved.